中国经济网北京1月6日讯 在刚过去的2025年12月份，平安基金共有12只（各份额分开计算，下 同）基金跌幅超过8%。平安港股通医疗创新精选混合C、平安港股通医疗创新精选混合A以13.52%和 13.48%的跌幅成为该公司旗下的垫底基金。 据悉，平安港股通医疗创新精选混合成立于2025年6月11日，由周思聪和张淼共同管理。周思聪曾 先后担任银华基金管理股份有限公司基金经理、长盛基金管理有限公司基金经理。2023年5月加入平安 基金管理有限公司，先后管理公募基金已经长达11年。而张淼曾历任北京中关村科技控股有限公司投资 管理部研究员、东方基金管理有限责任公司行业研究员，基金经理助理、嘉实基金管理有限公司研究部 副总监。2021年6月加入平安基金，现任权益投资部投资执行总经理、基金经理，累计管理经验也超过 10年。 该基金205年三季度前十大重仓股为诺诚健华、药明合联、康方生物、百济神州、科伦博泰生物、 信达生物、三生制药、中国生物制药、石药集团、联邦制药。 由于医药板块在去年的整体表现不佳，周思聪单独管理的其他多只基金跌幅紧随其后，这些基金分 别为平安医疗健康混合C、平安医疗健康混合A、平安医药精选股票C、平安 ...

Core Insights - The stock and mixed funds achieved a positive return of 70.27% on December 8, with 243 funds returning over 5% and 472 funds experiencing a net value drawdown exceeding 1% [1][2] Fund Performance - The Shanghai Composite Index rose by 0.54% to close at 3924.08 points, while the Shenzhen Component Index increased by 1.39%, the ChiNext Index by 2.60%, and the STAR 50 Index by 1.86% [1] - The top-performing sectors included telecommunications, comprehensive, and electronics, with increases of 4.79%, 3.03%, and 2.60% respectively. Conversely, coal, oil and petrochemicals, and food and beverage sectors saw declines of 1.43%, 0.84%, and 0.78% respectively [1] - The average net value growth rate for stock and mixed funds on December 8 was 0.80% [1] Top Funds - The fund with the highest net value growth rate was Guorong Rongxin Consumer Select Mixed C, achieving a growth rate of 10.01%. Other notable funds included Guorong Rongxin Consumer Select Mixed A (10.00%), and Guoshou Anbao Strategy Selected Mixed A (9.14%) [2] - Among the funds with a net value growth rate exceeding 5%, 142 were equity funds, 41 were flexible allocation funds, and 34 were index equity funds [2] Drawdown Analysis - A total of 472 funds experienced a drawdown exceeding 1%, with the largest drawdown recorded by Huatai-PB Hong Kong Stock Connect Medical Selected Mixed Initiated C, which saw a decline of 2.40% [2][4] - Other funds with significant drawdowns included Huatai-PB Hong Kong Stock Connect Medical Selected Mixed Initiated A (-2.40%), and Yin Hua Fu Li Selected Mixed C (-2.32%) [4]

Core Viewpoint - The article highlights the increasing prominence of female fund managers in the public fund industry, showcasing their performance and contributions to the sector as their representation grows [3][4]. Summary by Sections Female Fund Managers Overview - As of September 9, 2025, there are 3,868 active public fund managers, with 2,831 males (73.19%) and 1,037 females (26.81%) [3]. Performance of Female Fund Managers - The threshold for the top 10 female fund managers with over 10 years of experience this year is a return of 29.65% [4]. - Among these top performers, two managers from Ping An Fund achieved the highest returns [4]. Top Performing Female Fund Managers - The top female fund manager is Zhou Encong from Ping An Fund, with a return of 90.02% and a management scale exceeding 30 billion yuan [5][6]. - Other notable managers include Ge Lan from China Europe Fund, with a return of 38.66% and a management scale close to 400 billion yuan [6][7]. Fund Management Scale Insights - Among female fund managers, 304 manage over 10 billion yuan, and 72 manage over 50 billion yuan [9]. - The top female fund manager by scale is Cai Kaer from Fu Guo Fund, with a return of 40.99% and a management scale of approximately 588 billion yuan [10][11]. Performance in Active Equity Funds - There are 346 female active equity fund managers, with the top 20 this year having a return threshold of 53.49% [13]. - Zhou Shanshan from交银施罗德基金 leads with a return of 93.45% [14][15]. Investment Focus - Zhou Encong focuses on innovative drugs and believes 2025 will be a pivotal year for the industry [6]. - Ge Lan's top holdings are in the biopharmaceutical sector, indicating a strategic focus on healthcare [7][8]. Conclusion - The article emphasizes the growing influence and success of female fund managers in the public fund industry, reflecting a shift in the investment landscape towards greater gender diversity and performance excellence [3][4].

Group 1 - The article highlights the increasing prominence of female fund managers in the public fund sector, with women comprising 26.81% of the total 3,868 fund managers as of September 9, 2025 [1] - Among female fund managers, those with over 10 years of experience have a performance threshold of 29.65% to be in the top 10 this year [2] - The top-performing female fund manager, Zhou Sicong from Ping An Fund, achieved a return of 90.02% and manages four funds with a total scale exceeding 30 billion [4] Group 2 - Guo Lan from China Europe Fund leads in management scale among the top female fund managers, with nearly 40 billion in assets and a return of 38.66% [5] - The article notes that 304 female fund managers manage over 100 billion, with 72 managing over 500 billion, indicating a significant presence in the market [6] - Cai Kaer from Fortune Fund achieved the highest return of 40.99% this year, managing approximately 588 billion across 13 funds [8] Group 3 - The top 20 female active equity fund managers have a performance threshold of 53.49% this year, with Zhou Shanshan from交银施罗德基金 leading at 93.45% [9][13] - Zhou Shanshan's fund focuses on multiple asset classes and has significant holdings in the computing power sector, with her top stock, Xin Yisheng, rising by 81.97% [13] - The article emphasizes the strong performance of female fund managers in the context of a favorable A-share market this year [9]

Group 1 - The article provides a ranking of the top 10 open-end funds based on net asset value growth as of August 21, 2025, highlighting the performance of various funds [2][4][7] - The top-performing fund is "汇添富双鑫添利债券D" with a net value of 1.2019, showing a significant increase from 1.0000 [2] - The bottom-performing fund is "前海开源周期精选混合C," which has a net value of 1.0343, down from 1.0816 [4][7] Group 2 - The article notes that a total of 28,402 funds have updated their net values, indicating a broad market activity [3] - The sectors leading the market include multi-financial and telecommunications, both showing gains of over 2% [7] - The article mentions that the "万家中证港股通创新药ETF" has experienced rapid net value growth, indicating strong performance in the healthcare sector [7] Group 3 - The article discusses the concentration of holdings in the top funds, with "万家中证港股通创新药ETF" having a concentration of 67.67% in its top ten holdings, primarily in the pharmaceutical sector [8] - The top holdings in this fund include "信达生物" and "药明生物," which have shown significant daily increases [8] - Conversely, the "前海开源周期精选混合C" fund has a lower concentration of 58.34% in its top holdings, with notable declines in some of its key stocks [8]

Core Viewpoint - The A-share market has shown a clear bullish trend in 2023, with significant index breakthroughs, leading to impressive performance from many equity fund managers [4][5]. Group 1: Fund Manager Performance - As of August 15, 2023, there are 1,794 public fund managers with performance data, with the majority being new generation managers, achieving an average return of 20.68% for their equity funds [5]. - The performance of fund managers is categorized into three generations: - New Generation (less than 5 years): 901 managers, average return of 20.68% [5]. - Middle Generation (5-10 years): 635 managers, average return of 18.09% [5]. - Old Generation (10 years and above): 258 managers, average return of 16.78% [5]. - The total assets under management (AUM) for these fund managers amount to 55,735.04 billion [5]. Group 2: Top Fund Managers - The top five fund managers from the new generation include: - Liang Furui from Changcheng Fund with a return of 137.72% and AUM of approximately 1.1 billion [6][8]. - Chu Kefa and Ren Jie from Yongying Fund with returns of 122.30% and 108.97% respectively [6][9]. - The top five fund managers from the middle generation include: - Leng Wenpeng from CITIC Construction Investment Fund with a return of 104.73% and AUM of nearly 300 million [10][12]. - The top five fund managers from the old generation include: - Zhou Sicong from Ping An Fund with a return of 90.96% and AUM exceeding 3 billion [13][15]. Group 3: Investment Strategies - Liang Furui employs a unique three-cycle strategy focusing on demand and matching companies with demand cycles, particularly in the innovative drug sector [8]. - Chu Kefa combines quantitative risk control with active stock selection, favoring leading commercial companies and those with technological breakthroughs [9]. - Leng Wenpeng focuses on "specialized, refined, unique, and innovative" companies listed on the Beijing Stock Exchange [12]. - Zhou Sicong emphasizes a three-dimensional screening approach for innovative drug investments, predicting significant industry growth in 2025 [16].